NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) has dosed the first patient in a U.S. Phase 1 clinical trial of ARR-002, an experimental antibody-drug conjugate targeting ovarian and endometrial cancers, expanding the company’s clinical development pipeline beyond lung and gastrointestinal cancers.
The Newtown Square-based biopharmaceutical company is evaluating ARR-002, a dual-target antibody-drug conjugate designed to recognize two proteins, MUC16 and NaPi2b, that are frequently overexpressed in ovarian and endometrial tumors.
The treatment uses a tetravalent antibody structure to target both proteins, an approach intended to address differences in protein expression among cancer cells that can limit the effectiveness of therapies directed at a single target.
The first patient dosing marks the entry of ArriVent’s second antibody-drug conjugate into clinical testing. The Phase 1 study is registered as NCT07755436.
“Both MUC16 and NaPi2b are highly over-expressed in ovarian and endometrial cancer, and the dual targeting approach of ARR-002 is designed to overcome a key limitation of single-target ADCs in solid tumors,” said Stuart Lutzker, ArriVent’s president of research and development.
Antibody-drug conjugates combine antibodies that recognize specific targets on cancer cells with drugs intended to kill those cells. ARR-002’s dual-target design seeks to improve drug delivery in tumors where the expression of individual targets varies.
The initiation of clinical testing broadens ArriVent’s oncology development efforts into gynecologic cancers, complementing its existing programs in lung and gastrointestinal malignancies.
The clinical milestone follows an August 2026 licensing agreement with Shanghai Allist Pharmaceuticals Co. Ltd. covering ARR-002 development and commercialization in Greater China, including mainland China, Hong Kong, Macau and Taiwan.
ArriVent retained rights to the treatment outside those markets.
ARR-002 remains an investigational therapy, with the Phase 1 trial representing an early stage of clinical evaluation. Its potential effectiveness and safety in patients have not yet been established.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.